LIMMATECH BIOLOGICS
LimmaTech Biologics AG is a clinical-stage biopharmaceutical company.
LIMMATECH BIOLOGICS
Industry:
Biopharma Biotechnology
Status:
Active
Contact:
+41 44 733 8585
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Font Awesome
Similar Organizations
Alpha Biopharma
Alpha Biophama is a clinical stage biopharmaceutical company.
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biopharmaceutical company.
Mologen AG
Mologen AG is an internationally operating bio pharmaceutical company.
Current Employees Featured
Michael Kowarik CSO & Co-Founder @ LimmaTech Biologics
CSO & Co-Founder
2020-05-01
Paul Wolfrom Co-Founder & CFO @ LimmaTech Biologics
Co-Founder & CFO
2015-07-01
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-11-05 | GlycoEra | LimmaTech Biologics investment in Series A - GlycoEra | 45 M CHF |
More informations about "LimmaTech Biologics"
Company | LimmaTech Biologics AG
LimmaTech has pioneered vaccine development technologies to build a pipeline of vaccine programs to protect against and prevent severe infections caused by pathogens that have become resistant to antimicrobial treatments. ...See details»
LimmaTech Biologics AG - Swiss Biotech
LimmaTech Biologics AG is a Swiss clinical stage biopharmaceutical company. ... Type of organization. Private company. Year of foundation. 2015. Number of employees in …See details»
Pipeline & Clinical Trials | LimmaTech Biologics AG
LimmaTech Biologics AG is committed to combating AMR and sexually transmitted diseases with innovative vaccines. ... LimmaTech has evaluated candidate vaccines in several clinical trials …See details»
LimmaTech Biologics - Crunchbase Investor Profile
LimmaTech Biologics is a clinical-stage biotech company that develops vaccines to prevent life-threatening diseases. The company uses proprietary self …See details»
LimmaTech Biologics: USD 37 million for vaccines against …
Oct 9, 2023 LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo …See details»
LimmaTech Biologics AG - startup.ch
LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due …See details»
LimmaTech Biologics 2025 Company Profile: Valuation, Funding ...
LimmaTech Biologics General Information Description. Operator of a clinical-stage biopharmaceutical firm focused on the prevention of life-threatening diseases. The company …See details»
LimmaTech Biologics AG - VentureRadar
LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation pharmaceuticals using protein glycosylation …See details»
LimmaTech Biologics - Biotech Careers
LimmaTech Biologics AG is a Swiss clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to …See details»
LimmaTech Biologics Raises $37 Million Series A to Advance Its …
LimmaTech Biologics AG is applying its deep know-how of engineering complex molecules to develop next-generation vaccines to prevent life-threatening diseases. Spun out from ...See details»
LimmaTech Biologics Raises $37 Million Series A to Advance Its …
Oct 9, 2023 LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Al ... 5 World Health …See details»
LimmaTech Awarded FDA Fast Track Designation for Vaccine
Dec 20, 2024 SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening …See details»
AXA IM Alts invests CHF 14m (€14.5m) into biotechnology …
Oct 9, 2023 AXA IM Alts, a global leader in alternative investments with over €185 billion of assets under management, [1] announces a CHF 14 million (€14.5 million) investment as part …See details»
LimmaTech sets up as de facto GSK vaccine R&D unit in wake of …
Sep 3, 2015 LimmaTech Biologics, a spillover from the $190 million (€169 million) takeover of GlycoVaxyn by GlaxoSmithKline, has opened its doors. The biotech is starting life with …See details»
LimmaTech Biologics - Funding, Financials, Valuation & Investors
LimmaTech Biologics is a biotech company that develops vaccines to prevent microbial infections and address antimicrobial resistance. New. Resources. Advanced Search. ... How much …See details»
LimmaTech Biologics AG: Revenue, Worth, Valuation
About LimmaTech Biologics AG. LimmaTech Biologics AG is a Biotech related company founded in 2015 and based in Schlieren with 49 employees an estimated revenue of $6.7M, and. It has …See details»
Careers | LimmaTech Biologics AG
LimmaTech Biologics AG is located in Schlieren, very close to Zurich, and is easily reachable by car or public transport. We are only a 5-minute walk from the Schlieren train station. …See details»
LimmaTech Biologics Raises $37 Million Series A to Advance
Oct 9, 2023 LimmaTech Biologics AG announced the closing of a USD 37 million Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR …See details»
GlaxoSmithKline signs on LimmaTech for vaccine R&D
Sep 3, 2015 That company is LimmaTech Biologics, which announced the start of its operations on Friday. When GlaxoSmithKline bought out GlycoVaxyn for $190 million early this year, it …See details»
FUJIFILM signs $3B deal with Regeneron for biologics work in …
Apr 22, 2025 FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations in North Carolina, has signed an …See details»